Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Jeffery Moran

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmacology & Toxicology, College of Medicine
DivisionPharmacology Research
AddressB306 Biomedical Research I
325 S. Elm St.
Mail Slot # 611
Little Rock AR 72205
Phone501-686-5510
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    UG1HD107650     (HALL, RICHARD WHITTINGTON)Sep 17, 2021 - Aug 31, 2026
    NIH
    HEAL Initiative: Neonatal Opioid Withdrawal Syndrome Pharmacological Treatments Comparative Effectiveness Trial Clinical Site
    Role: Co-Investigator
    W81XWH2110226     (HSU, PING-CHING)Apr 1, 2021 - Mar 31, 2024
    US Department of Defense
    Metabolomics of menthol cigarette smoking and risk for aggressive prostate cancer among African-American men
    Role: Principal Investigator
    ACRI # 035723     (MORAN, JEFFERY H)Jul 1, 2016 - Jun 30, 2019
    UAMS ACHRI Flow Through
    No FP attached
    Role: Principal Investigator
    ACRI # 037104     (MORAN, JEFFERY H)Jul 1, 2016 - Jun 30, 2019
    UAMS ACHRI Flow Through
    No FP attached
    Role: Principal Investigator
    ACRI #TBD     (MORAN, JEFFERY H)Jul 1, 2016 - Jun 30, 2019
    UAMS ACHRI Flow Through
    No FP attached
    Role: Principal Investigator
    R01DA039143     (PRATHER, PAUL L)May 15, 2016 - Apr 30, 2021
    NIH
    Synthetic Cannabinoid Toxicity: Role of Biotransformation
    Role: Co-Investigator
    R21CA152555     (BORRELLI, MICHAEL JUDE)Apr 1, 2011 - Mar 31, 2015
    NIH
    Reduced Temperature Thermal Ablation for HCC and other Liver Tumors
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Avram M, Bodinger CA, Clark MA, Stuckey DG, Mathews SE, Stogsdill SN, Barna EC, Williams DK, McGill M, Fantegrossi WE, Liebelt EL, James LP, Endres GW, Moran JH. Hands-Free Analytical Urine Testing Technology Validated for Drug-Facilitated Crime Investigations. Chem Res Toxicol. 2023 Sep 13. PMID: 37703190.
      View in: PubMed
    2. Janganati V, Salazar P, Parks BJ, Gorman GS, Prather PL, Peterson EC, Alund AW, Moran JH, Crooks PA, Brents LK. Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats. Front Pharmacol. 2023; 14:1123261. PMID: 37229250.
      View in: PubMed
    3. Mack JM, Peterson EC, Crary SE, Moran JH, Neville K, Pierce CD, Richter GT. Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations. Pediatr Blood Cancer. 2022 08; 69(8):e29733. PMID: 35484878.
      View in: PubMed
    4. Steele RW, Moran JH, Patton AL, Kokes CP, James LP, Storm EA, Schexnayder SM. The Spice of Death: Sudden Cardiac Arrest After Novel Psychoactive Substance Exposure. Pediatr Emerg Care. 2022 Jan 01; 38(1):e63-e64. PMID: 34534160.
      View in: PubMed
    5. McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon-McGill S, Spencer HJ, Dranoff JA. Short-Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatol Commun. 2022 02; 6(2):361-373. PMID: 34558847.
      View in: PubMed
    6. Moran JH, Kessler L, Moylan J, Forrest C, Boehme K, Kennedy J, Greninger A, Baird G, Olgaard E, James L. Modifying laboratory testing via home brew during the COVID-19 pandemic. J Clin Transl Sci. 2021 Jan 25; 5(1):e93. PMID: 34192050.
      View in: PubMed
    7. Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. J Pharmacol Exp Ther. 2019 07; 370(1):9-17. PMID: 31028107.
      View in: PubMed
    8. Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to ?9-THC. Front Pharmacol. 2018; 9:1084. PMID: 30319418.
      View in: PubMed
    9. Patton AL, Jones JO, Nord A, Eversole DW, Feazell EE, Mauldin K, Li L, Williams LD, Bai S, Channell K, Endres G, Gamette M, Moran JH. Multi-laboratory validation of a ?9-tetrahydrocannabinol LC-MS/MS test kit designed for quantifying THC and marijuana metabolites in blood. Forensic Sci Criminol. 2018; 3(1). PMID: 29955732.
      View in: PubMed
    10. Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochem Biophys Res Commun. 2018 04 06; 498(3):597-602. PMID: 29522717.
      View in: PubMed
    11. Pfannkoch EA, Stuff JR, Whitecavage JA, Blevins JM, Seely KA, Moran JH. A High Throughput Method for Measuring Polycyclic Aromatic Hydrocarbons in Seafood Using QuEChERS Extraction and SBSE. Int J Anal Chem. 2015; 2015:359629. PMID: 25873967.
      View in: PubMed
    12. Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Anal Chem. 2014 Feb 04; 86(3):1760-6. PMID: 24354295.
      View in: PubMed
    13. Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013 Dec 10; 233(1-3):416-22. PMID: 24314548.
      View in: PubMed
    14. Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. Not simply synthetic tetrahydrocannabinol. J Pediatr. 2013 Dec; 163(6):1797-8. PMID: 24128645.
      View in: PubMed
    15. Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to ?(9)-THC: mechanism underlying greater toxicity? Life Sci. 2014 Feb 27; 97(1):45-54. PMID: 24084047.
      View in: PubMed
    16. Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Anal Chem. 2013 Oct 01; 85(19):9390-9. PMID: 23987522.
      View in: PubMed
    17. Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci. 2013 Nov; 58(6):1676-80. PMID: 23822805.
      View in: PubMed
    18. Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol. 2013 Jun 01; 269(2):100-8. PMID: 23537664.
      View in: PubMed
    19. Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH. Sulfaphenazole and a-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett. 2013 Mar; 7(1):34-8. PMID: 24329780.
      View in: PubMed
    20. Moran CL, Lackey FD, Patton AL, Moran JH, James LP, Fantegrossi WE, Prather PL, Radominska-Pandya A, McCain KR. Developing a Model Statewide Forensic Surveillance and Toxicology Testing Program for Designer Drugs,. 2013.
    21. Seely KA, Patton AL, Trass M, Miranda A, Moran JH. Development of a chiral LC-MS/MS approach for measuring metabolites of the synthetic cannabinoids JWH-018 and AM2201. MSACL. 2013.
    22. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012 Nov; 40(11):2174-84. PMID: 22904561.
      View in: PubMed
    23. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 03; 39(2):234-43. PMID: 22561602.
      View in: PubMed
    24. Seely KA, Brents LK, Radominska-Pandya A, Endres GW, Keyes GS, Moran JH, Prather PL. A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol. 2012 Apr 16; 25(4):825-7. PMID: 22404317.
      View in: PubMed
    25. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012 Apr 01; 83(7):952-61. PMID: 22266354.
      View in: PubMed
    26. Stratton SL, Henrich CL, Matthews NI, Bogusiewicz A, Dawson AM, Horvath TD, Owen SN, Boysen G, Moran JH, Mock DM. Marginal biotin deficiency can be induced experimentally in humans using a cost-effective outpatient design. J Nutr. 2012 Jan; 142(1):22-6. PMID: 22157538.
      View in: PubMed
    27. Moran JH. Smart resource allocation needed to study 'legal highs'. Nat Med. 2011 Nov 07; 17(11):1339. PMID: 22064403.
      View in: PubMed
    28. Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, Radominska-Pandya A. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2012 Jan; 340(1):46-55. PMID: 21972237.
      View in: PubMed
    29. Lapoint J, James LP, Moran CL, Nelson LS, Hoffman RS, Moran JH. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol. 2011; 49(8):760-4 (PMID: 21970775).
    30. Mock DM, Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Dawson AM, Spencer HJ, Owen SN, Boysen G, Moran JH. Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. J Nutr. 2011 Nov; 141(11):1925-30. PMID: 21918059.
      View in: PubMed
    31. Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem. 2011 Aug 15; 83(16):6381-8. PMID: 21740038.
      View in: PubMed
    32. Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, James LP, Moran JH, Radominska-Pandya A. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2011 Oct; 39(10):1967-76. PMID: 21746969.
      View in: PubMed
    33. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 2011; 6(7):e21917. PMID: 21755008.
      View in: PubMed
    34. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem. 2011 Jun 01; 83(11):4228-36. PMID: 21506519.
      View in: PubMed
    35. Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011 Feb; 11(1):36-51. PMID: 21441120.
      View in: PubMed
    36. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, Mock DM. Urinary excretion of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. J Nutr. 2011 Mar; 141(3):353-8. PMID: 21248194.
      View in: PubMed
    37. Chimalakonda KC, Brents LK, Moran CL, Prather PL, James LP, Radominska-Pandya A, Moran JH. Simultaneous Urinary Identification and Quantification and In Vitro Characterization of Omega and Omega-1 Metabolites of the abused synthetic cannabinoids JWH-018 and JWH-073,. International Society for the Study of Xenobiotics (ISSX). 2011.
    38. James LP, Moran JH, Moran CL. K2, Summit, and Spice: Fake Weed is not so nice. Medical Laboratory Observer. 2011; 43(4):36.
    39. Viswanathan T, Gunawan G, Shawnbourdo, Saini V, Moran JH, Pack L, Owen S. Journal of Macromolecular Science, Part A: Pure and Applied Chemistry. Evaluation of a Renewable Resource-based Carbon Iron Oxide Nanocomposite for Removal of Arsenic from Contaminated Water. 2011; 48, 348-354.
    40. Horvath TD, Stratton SL, Bogusiewicz A, Owen SN, Mock DM, Moran JH. Quantitative measurement of urinary excretion of 3-hydroxyisovaleryl carnitine by LC-MS/MS as an indicator of biotin status in humans. Anal Chem. 2010 Nov 15; 82(22):9543-8. PMID: 21028833.
      View in: PubMed
    41. Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Spencer HJ, Moran JH, Mock DM. Plasma concentration of 3-hydroxyisovaleryl carnitine is an early and sensitive indicator of marginal biotin deficiency in humans. Am J Clin Nutr. 2010 Dec; 92(6):1399-405. PMID: 20943794.
      View in: PubMed
    42. Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol. 2010 May 17; 23(5):939-45. PMID: 20429590.
      View in: PubMed
    43. Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J, Mock DM. Quantitative measurement of plasma 3-hydroxyisovaleryl carnitine by LC-MS/MS as a novel biomarker of biotin status in humans. Anal Chem. 2010 May 15; 82(10):4140-4. PMID: 20397702.
      View in: PubMed
    44. Jones DR, Moran JH, Miller GP. Warfarin and UDP-glucuronosyltransferases: writing a new chapter of metabolism. Drug Metab Rev. 2010 Feb; 42(1):55-61. PMID: 19788348.
      View in: PubMed
    45. Moran JH. K2 Method Development at the Arkansas Public Health Laboratory. Lab Matters. 2010; 4:13.
    46. Miller GP, Jones DR, Sullivan SZ, Mazur A, Owen SN, Mitchell NC, Radominska-Pandya A, Moran JH. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans. Chem Res Toxicol. 2009 Jul; 22(7):1239-45. PMID: 19408964.
      View in: PubMed
    47. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009 Jul; 37(7):1496-504. PMID: 19339377.
      View in: PubMed
    48. Miller GP, Lichti CF, Zielinska AK, Mazur A, Bratton SM, Gallus-Zawada A, Finel M, Moran JH, Radominska-Pandya A. Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin. Drug Metab Dispos. 2008 Nov; 36(11):2211-8. PMID: 18725508.
      View in: PubMed
    49. Zielinska A, Lichti CF, Bratton S, Mitchell NC, Gallus-Zawada A, Le VH, Finel M, Miller GP, Radominska-Pandya A, Moran JH. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther. 2008 Jan; 324(1):139-48. PMID: 17921187.
      View in: PubMed
    50. Nowak G, Grant DF, Moran JH. Linoleic acid epoxide promotes the maintenance of mitochondrial function and active Na+ transport following hypoxia. Toxicol Lett. 2004 Mar 01; 147(2):161-75. PMID: 14757320.
      View in: PubMed
    51. Mitchell LA, Moran JH, Grant DF. Linoleic acid, cis-epoxyoctadecenoic acids, and dihydroxyoctadecadienoic acids are toxic to Sf-21 cells in the absence of albumin. Toxicol Lett. 2002 Feb 07; 126(3):187-96. PMID: 11814707.
      View in: PubMed
    52. Moran JH, Nowak G, Grant DF. Linoleic acid monoepoxides directly uncouple rabbit cortical mitochondria and conversion to dihydroxy metabolites prevents uncoupling. Toxicological Sciences. 2001.
    53. Mitchell LA, Moran JH, Mon T, Grant DF. Distinct mechanisms of toxicity for linoleic acid monoepoxides and diols in sf-21 cells. 2000.
    54. Moran JH, Mitchell LA, Schnellmann RG, Grant DF. Linoleic acid metabolites induce renal cell death at pathologically relevant concentrations. Toxicological Sciences. 2000; 1879.
    55. Harriman JF, Liu X, Moran JH, Schnellmann RG. Glycine, strychnine, muscimol and thapsigargin block increases in cytosolic free Ca2+ levels in renal cell injury. Toxicological Sciences. 1999; 114.
    56. Moran JH, Frame LT, Minchin RF, Massengill J, Lang NP, Kadlubar FF. Comparison of N-acetyltransferase-1 (NAT1) activity in human lymphocytes, platelets, and liver. International Society for the Study of Xenobiotics Proceedings. 1997; 195.
    57. Moran JH, Schnellmann RG. Diverse cytoprotectants prevent cell death and promote the recovery of respiration and ion transport. Fundamentals and Applied Toxicology. 1997; 149.
    58. Radominska-Pandya A, Yiew KH, Bratton SM, Gallus-Zawada AE, Fantegrossi WE, James LP, Moran C, Prather P, Moran JH. Biotransformation of abused synthetic cannabinoids in K2/Spice by human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs). 4th Asia Pacific Regional ISSX Meeting.
    59. Mazur A, Xiong Y, Lichti CF, Zielinska AK, Moran JH, Miller GP, Finel M, Radominska-Pandya A. Substrate Binding and Specificity of Human UGT1A10. 12th International Glucuronidation and UGT International Workshop 2008.
    60. Cortez LK, Reichard EE, Moran JH, Fantegrossi WE, Prather PL. Hydroxylated metabolites of the synthetic cannabinoid JWH-018 retain in vitro and in vivo affinity and activity at CB1 cannabinoid receptors. Experimental Biology 2010.
    61. Moran JH, Lanza J, Brown D. Fly preferences for and nutritional benefits of nectar-borne amino acids.
    62. Radominska-Pandya A, Chimalakonda KC, Bratton SM, Fedejko-Kap B, Le V-H, Yiew KH, Moran CL, James LP, Moran JH. Biotransformation of Abused Synthetic Cannabinoids, JWH-018 and JWH-073, by Human Cytochromes P450 and UDP-glucuronosyltransferases. 17th North American Regional ISSX Meeting.
    63. Radominska-Pandya A, Yiew KH, Bratton SM, Le V-H, Gallus-Zawada AE, Moran C, James LP, Moran JH. Conjugation of synthetic cannabinoids in K2/Spice by human UDP-glucuronosyltransferase (UGTs). Experimental Biology 2011.
    64. Brents LK, Gallus-Zawada A, Radominska-Pandya A, Fantegrossi WE, Moran JH, Prather PL. A mono-hydroxylated metabolite of the K2 synthetic cannabinoid JWH-073 displays high affinity neutral antagonism at CB1 receptors. 21st Annual Symposium of the International Cannabinoid Research Society.
    65. Radominska-Pandya A, Miley M, Xiong Y, Mazur A, Zielinska AK, Bratton SM, Gallus-Zawada A, Miller GP, Finel M, Moran JH, Redinbo M. Identification and Characterization of the UDP-glucuronic Acid and Substrate Binding Sites of Human UDP-glucuronosyltransferases: Crystallization and Photoaffinity Labeling. 15th North American Regional ISSX meeting.
    66. Stratton S, Horvath T, Owen S, Moran JH, Mock DM. The relationship between fetal biotin status and cleft palate in a single pair of fraternal twins. Experimental Biology 2011.
    67. Chimalakonda KC, Brents LK, Moran CL, Prather PL, James LP, Radominska-Pandya A, Moran JH. Human Metabolism of JWH-018 and JWH-073 and In Vitro Characterization of Major Omega and Omega-1 Metabolites. 17th North American Regional ISSX Meeting.
    68. Radominska-Pandya A, Mazur A, Lichti CF, Gallus-Zawada A, Zielinska AK, Bratton SM, Moran JH. Human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs) enzymes involved in the metabolism of cannabinoids. Experimental Biology 2008.
    69. Moran JH, Le VH, Blevins JM, Moran CL, Bratton SM, Chib S, Gallus-Zawada A, Prather PL, Fantegrossi WE, Wessinger WE, Radominska-Pandya A, James LP. Combining innovation with translational science to develop a model statewide forensic testing and biomonitoring program in Arkansas.
    70. Moran JH, Nowak G, Grant DF. Cis-12,13-epoxy-9-octadecenoic acid uncouples oxidative phosphyorlation in rabbit cortical mitochondria and conversion to 12,13-dihydroxy-9-octadecenoic acid prevents uncoupling.
    71. Zielinska AK, Lichti CF, Bratton SM, Gallus-Zawada A, Mitchell NC, Moran JH, Radominska-Pandya A. Glucuronidation of Hydroxylated Derivatives of Warfarin by Human UGT1A10; Identification of Amino Acid Motif Involved in Warfarin Binding. 8th International ISSX meeting.
    72. Jones DR, Kim S-Y, Guderyon M, Yun C-H, Radominska-Pandya A, Moran JH, Miller GP. Cytochrome P450 Capacity to Metabolize Warfarin Limited by Feedback Inhibition. 16th North American Regional ISSX meeting.
    73. Radominska-Pandya A, Mazur A, Bratton SM, Finel M, Moran JH, Miller GP. Simultaneous glucuronidation of native and oxidized estrogens and warfarin by human recombinant UGT1A10: Potential for drug-drug interactions. 3rd Asian Pacific ISSX Meeting.
    74. Zielinska A, Lichti CF, Bratton SM, Gallus-Zawada A, Mitchell NC, Finel M, Radominska-Pandya A, Moran JH. Glucuronidation of Warfarin Metabolites by Human Recombinant UDP-Glucuronosyltransferases (UGTs). Experimental Biology 2007.
    75. Moran JH, Pack LM, Gallus-Zawada AE, Yew N, Bratton SM, Owen SN, Jones DR, Miller GP, Radominska-Pandya A. Separation and Glucuronidation of R- and S-Hydroxywarfarins by Human Recombinant UDP-Glucuronosyltransferases (UGTs). 16th North American Regional ISSX meeting.
    76. Radominska-Pandya A, Yiew KH, Bratton SM, Gallus-Zawada A, Fantegrossi WE, James LP, Moran CL, Prather PL, Moran JH. Biotransformation of abused synthetic cannabinoids in K2/Spice by human hepatic and extrahepatic UDP-glucuronosyltransferase (UGTs). International Society for the Study of Xenobiotics (ISSX).
    77. Radominska-Pandya A, Bratton SM, Chib S, Blevins JM, Gallus-Zawada AE, Moran C, James LP, Moran JH. Oxidation of abused synthetic cannabinoids in K2/Spice by human cytochromes P450. Experimental Biology 2011.
    78. Brents LK, Rajesekaran M, Franks L, Moran JH, Prather PL. The omega and omega-1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s). Experimental Biology.
    79. Mock D, Horvath T, Stratton S, Bogusiewicz A, Moran JH. Urinary excretion of 3-hydroxyisovaleryl carnitine (3HIAC) in response to a leucine load increases in marginal biotin deficiency. Experimental Biology 2011.
    80. Moran JH, Jones D, Bratton SM, Gallus-Zawada AE, Miller GP, Radominska-Pandya A. Separation and Glucuronidation of R- and S-Hydroxywarfarins by Human Recombinant UDP-Glucuronosyltransferases (UGTs). 3rd Asian Pacific ISSX Meeting.
    Moran's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (186) concept(s)
    _
    Co-Authors Expand Description
    See all (21) people
    _
    Similar People Expand Description
    See all (34) people
    _
    Same Department Expand Description
    Search Department